The study included patients with non-small-cell lung, pancreatic, and colorectal cancer ... Patients were to receive a ...

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

Are you looking for nutrients to support your brain health? Choline can make an impactful difference, so discover 13 ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

The following is a summary of “Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year ...

The CFTR protein reaches the cell membrane but the channel does not ... or placebo for 28 days Part 1 Group 1 (n = 4) VX-770 25 mg twice daily, then VX-770 75 mg twice daily Group 2 (n = 4 ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

The researchers say their approach to solar cell construction – outlined in Ultra-Lean Silver Screen-Printing for Sustainable ...

NextCure (NXTC) reported pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate, or ADC, being developed in partnership with ...